RemeGen (REGMF) Stock Price, News & Analysis

Company Overview

RemeGen Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of targeted therapeutic antibodies and antibody–drug conjugates (ADCs) for oncology and other serious diseases. Headquartered in Yantai, Shandong Province, China, the company leverages proprietary antibody engineering platforms to advance treatments that may offer improved efficacy and safety profiles compared with conventional therapies. RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is an ADC designed to target HER2-expressing tumors and is under regulatory review in China for multiple cancer indications.

In addition to RC48, RemeGen is developing a robust pipeline of antibody-based therapies. These include RC28, a dual-target immunocytokine aimed at both immune checkpoint modulation and anti-angiogenesis, and other next-generation ADCs focused on EGFR and other tumor-associated antigens. The company’s proprietary antibody discovery platforms—Covalink, MabSelect, and RemeShore—support the rapid identification and optimization of high-affinity candidates, enabling streamlined development from target validation through clinical evaluation.

Since its founding in 2013, RemeGen has pursued a strategy of global collaboration and market expansion. The company went public on the Hong Kong Stock Exchange in 2019 and maintains an over-the-counter listing in the United States under the symbol REGMF to facilitate international investor participation. RemeGen maintains strategic partnerships and licensing agreements with leading pharmaceutical companies in Europe, North America and Asia, positioning its pipeline to address global oncology markets and unmet medical needs.

RemeGen’s executive leadership is led by Chairman and Chief Executive Officer Haichang Zhang, whose background in biopharmaceutical R&D and strategy has guided the company’s transition from discovery-stage research to late-stage clinical development. Supported by a management team with deep expertise in regulatory affairs, manufacturing and global commercialization, RemeGen continues to advance its mission of delivering innovative antibody-based therapies to patients worldwide.

Key Stats

• Today's Range: $5.06 to $5.06
• 50-Day Range: $5.06 to $5.06
• 52-Week Range: $1.50 to $5.10
• Volume: N/A
• Average Volume: 550 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REGMF Stock Analysis - Frequently Asked Questions

How have REGMF shares performed this year?

RemeGen's stock was trading at $1.50 at the start of the year. Since then, REGMF shares have increased by 237.3% and is now trading at $5.06.

How do I buy shares of RemeGen?

Shares of REGMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/29/2025
• Next Earnings (Estimated): 8/14/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:REGMF
• CIK: N/A
• Web: www.remegen.com
• Phone: 86-53-56357-3672
• Fax: N/A
• Employees: 3,615
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A